UNESCO Honors Nancy Ip for Alzheimer's Research
The international life sciences prize recognizes Ip's biomarker discoveries and blood tests aimed at earlier Alzheimer's diagnosis.
Updated on Nov. 7, 2026 in Alzheimer’s
UNESCO presented Nancy Ip, president of the Hong Kong University of Science and Technology, with the Unesco-Equatorial Guinea International Prize for Research in the Life Sciences on Friday in Paris. The award recognizes her work on new Alzheimer's biomarkers, genetic risk factors and blood tests for earlier diagnosis.
Why it matters
Earlier detection of Alzheimer's through blood-based tests could allow diagnosis before symptoms become severe, a central goal in the field. UNESCO's recognition highlights the role of cross-disciplinary cooperation in developing treatments for the disease.
The award is a recognition of research outputs rather than a clinical trial result, and the source provides no sample sizes or efficacy figures for the biomarkers or blood tests. Available detail is limited to the discoveries themselves, leaving their validation and deployment status unspecified.
The players
Nancy Ip
Ip is president of the Hong Kong University of Science and Technology and a member of the Chinese Academy of Sciences, known for neuroscience and Alzheimer's research.
UNESCO
The United Nations Educational, Scientific and Cultural Organization established the prize in 2008 to recognize contributions to the life sciences.
The details
Ip's research has led to the discovery of new Alzheimer's biomarkers, the identification of genetic risk factors, and the development of blood tests enabling earlier diagnosis. She has also conducted gene therapy research for neurodegenerative diseases and is a member of the Chinese Academy of Sciences.
Timeline
2008: UNESCO established the prize, funded by the Republic of Equatorial Guinea.
Friday, November 6, 2026: Ip received the prize in Paris.
Big Picture
The UNESCO-Equatorial Guinea prize, founded in 2008, has recognized life sciences research over nearly two decades, and this year's award to Ip continues its focus on neurodegenerative disease. The recognition follows a broader international effort to move Alzheimer's diagnosis earlier through biomarkers and blood-based testing.
For people concerned about memory decline, blood-based tests may eventually offer an earlier and less invasive route to diagnosis than current methods. Any new test's availability and cost in everyday care will depend on regulatory approval and clinical adoption, which the source does not address.
The takeaway
Early diagnosis of Alzheimer's is increasingly being pursued through biomarkers and blood tests rather than late-stage symptom assessment. Readers following the disease should watch for how these tests move from research into clinical use.
Further reading
For more on the disease at the center of this research, see our Alzheimer's coverage.
